Dr. Reddy's Laboratories Cash Flow - Quarterly (NYSE:RDY)

Add to My Stocks
$34.07 $0.18 (0.53%) RDY stock closing price Jun 22, 2018 (Closing)

For analyzing any company like Dr. Reddy's Laboratories from an investment perspective, its important to check the cash flow statement. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Dr. Reddy's Laboratories profits and Dr. Reddy's Laboratories debt. Dr. Reddy's Laboratories stock analysis shows positive net income cash flow of $106M till 2018 Q3. This statement is important because profits alone cannot pay employees, or bills. Cash is required. Dr. Reddy's Laboratories has a negative cash and cash equivalents change of $-29M.

View and download details of Dr. Reddy's Laboratories cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Apr - Mar2018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q3
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow136M88M43M174M124M83M40M155M110M
Net Increase (Decrease) in Assets Liabilities-108M-91M-86M-83M-98M-42M5M-3M-25M
Cash From (used in) Discontinued Operations---------
Other Adjustments Net57M21M2M54M36M11M13M168M105M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-121M-84M-43M-188M-136M-95M-48M-180M-131M
Acquisition Disposition of Subsidiaires------436M-120M-120M
Increase (Decrease) in Investments-104M5M42M337M322M252M-197M16M51M
Other Cash Inflow (Outflow) from Investment Activities-20M-4M-4M-433M-410M-416M-62M-24M-31M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares----242M-231M-236M-232M--
Issuance (Repayment) of Debt Securities297M291M293M-80M-77M-1M--177M-176M
Increase (Decrease) in Bank & Other Borrowings-194M-229M-268M332M420M401M52M-4M10M
Payment of Dividends & Other Cash Distributions-63M-61M--52M-50M-51M--62M-62M
Other Cash from (used by) Financing Activities-15M-10M-5M-14M-8M-5M-2M-14M-11M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash---1M-8M-5M-5M-1M-65M-6M
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year76M81M136M84M135M111M147M120M137M
Cash & Equivalents at Year End30M37M44M59M89M35M94M74M89M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Dr. Reddy's Laboratories stock comparison chart provides an easy way to compare the stock price with peers along with details of Dr. Reddy's Laboratories stock price history.
The statement of cash flows can be categorized into the following main sections:

  • Dr. Reddy's Laboratories had a Net Change in Cash and Cash Equivalents of $-29M in the latest quarter 2018 Q3. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Dr. Reddy's Laboratories stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Dr. Reddy's Laboratories gained $192M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: Dr. Reddy's Laboratories used $-246M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $25M for Dr. Reddy's Laboratories.

Key Financial Ratios For Dr. Reddy's Laboratories Cash Flow

FCF margin

Quarterly Cash Flow Statements For Dr.Reddy's Laboratories Ltd (ADR) Peers

ASPEN PHARMACR cash flow, Mylan cash flow, Novartis cash flow, Sanofi cash flow, Teva Pharmaceutical cash flow